Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
Michel Dard of BioCellgraft Wins Business Worldwide Magazines 2025 CEO Award [Yahoo! Finance]
Celularity (NASDAQ:CELU) was upgraded by analysts at WBB Securities from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock.